Citation Impact
Citing Papers
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
The potential for artificial intelligence in healthcare
2019 Standout
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
2014 Standout
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
2012 Standout
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
2011
Targeting NF-κB in hematologic malignancies
2006
Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors
2006
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
NF- B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome
2005
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome
2008
A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia
2017
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML
2008
Allogeneic Transplantation for the Elderly Patient With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
2006
Acute leukemia as a secondary malignancy in children and adolescents: Current findings and issues
2008
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
2015
NF-κB and IKK as therapeutic targets in cancer
2006 Standout
Investigational Janus kinase inhibitors
2013
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
2010 Standout
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
Cardioprotective effect of metoprolol and enalapril in doxorubicin‐treated lymphoma patients: A prospective, parallel‐group, randomized, controlled study with 36‐month follow‐up
2010
Risk score for outcome after allogeneic hematopoietic stem cell transplantation
2009
Idarucizumab for Dabigatran Reversal
2015 Standout
Guidelines for the use of platelet transfusions
2016
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
2012 StandoutNobel
Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?
2006
Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission
2007
Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys
2008
Cancer-related inflammation and treatment effectiveness
2014 Standout
Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning
2006
Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation
2009
Therapeutic potential of cytokine and chemokine antagonists in cancer therapy
2006
Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
2013
2019
Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology
2006
Acute Myeloid Leukemia
2015 Standout
Current concepts in the diagnosis and management of cytokine release syndrome
2014 Standout
Regulation and Function of NF-κB Transcription Factors in the Immune System
2009 Standout
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
2015
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
2017
Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia in First or Subsequent Remission: Weighing Prognostic Markers Predicting Relapse and Risk Factors for Non-relapse Mortality
2008
Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloid Sarcoma: A Retrospective Study From the SFGM-TC
2008
Graft-versus-leukemia effects of transplantation and donor lymphocytes
2008
Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes
2013
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery
2006
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all
2014
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns
2010
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Exosomes as drug delivery vehicles for Parkinson's disease therapy
2015 Standout
Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
2014
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
2008
Chronic Inflammation and Cytokines in the Tumor Microenvironment
2014 Standout
Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia
2020 Standout
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
2014
Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation
2014
Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells
2018 Science
Works of Bart L. Scott being referenced
Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
2005
Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation
2007
Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
2010
Optimization of allogeneic transplant conditioning: not the time for dogma
2006
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis
2005
Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells
2004
Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome
2004
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
2012
Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders
2008
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study
2017
Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities
2010
Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
2014
Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage Dysplasia
2007
Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia
2007
Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.
2015
Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis
2010
Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.
2009
Delayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndrome
2016
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders
2007
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS
2012
Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.
2020
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study
2014
A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
2016
NF-κB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)
2005
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
2015
Targeted Busulfan and Cyclophosphamide as Compared to Busulfan and TBI as Preparative Regimens for Transplantation in Patients with Advanced MDS or Transformation to AML
2004
Comorbidity and Disease Status–Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation
2007
Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.
2015